Humedics Partners with Exosystemtec to Develop Exosome Therapeutics

[Asia Economy Reporter Chunhee Lee] Humedix is embarking on the development of therapeutics using the next-generation drug delivery system, 'exosomes.'

On the 4th, Humedix announced on the 5th that it signed a 'business agreement for the development of exosome-based therapeutics and cosmetics' with Exostemtech at its headquarters in Pangyo, Seongnam-si, Gyeonggi Province.

Exostemtech is a domestic bio venture company possessing technologies for mass production, analysis, and quality control of exosomes. It holds core technology for exosome-based protein drug delivery systems and is developing treatments for degenerative arthritis, liver fibrosis, and pulmonary fibrosis based on stem cell exosomes.

Exosomes are vesicles secreted by cells, measuring 50 to 150 nm (nanometers) in size. They contain substances such as ribonucleic acid (RNA), proteins, and metabolites, and have the function of restoring tissues or organs when damaged. Acting as messengers involved in intercellular signal transmission, exosomes are attracting attention as next-generation drug delivery systems. Exosome therapeutics are gaining more attention as biomarkers have been commercialized in the disease diagnosis field. They are known to have superior efficacy and higher safety with fewer side effects compared to existing cell therapies.

According to market research firm DBMR Research, the global exosome market was $11.774 billion (approximately 14 trillion KRW) last year. It is expected to grow at an average annual rate of about 21.9% to reach $31.692 billion (approximately 38 trillion KRW) by 2026.

Humedix plans to explore areas where exosome therapeutics can be developed by comprehensively considering the technologies, capabilities, and business areas of both companies and to promote joint research. They also plan to pursue collaboration in esthetic and beauty fields such as cosmetics, where exosomes are actively used.

Jinhwan Kim, CEO of Humedix, said, “Exosomes are a field attracting global pharmaceutical and bio companies’ attention as their potential applications are being recognized not only in disease diagnosis but also in therapeutics and cosmetics.” He added, “The meeting of Exostemtech and Humedix is expected to create synergy.”

This content was produced with the assistance of AI translation services.